Tag: John Crowley

A total of 10 posts are filed under John Crowley
Amicus Announces Positive Data in First Fabry Phase 3 Study
Amicus Therapeutics, a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced positive 12-… Continue Reading
JPMorgan Dad Turns Biotech CEO in Quest to Save his Son
Ilan Ganot, a hedge fund banker at JPMorgan Chase & Co. (JPM), left his life in finance to create a new business model aimed at developing… Continue Reading
Lance Legislation Designed to Help Patients with Chronic Diseases and Disabilities
Lawmaker joins noted rare disease advocates in effort WASHINGTON, D.C.– Congressman Leonard Lance (NJ 07) today announced he has… Continue Reading
John Crowley Talks About the Fifth Prescription Drug User Fee Act
On the last day of the World Orphan Drug Congress, John Crowley, Chairman and CEO, Amicus Therapeutics provided an inspiring overview of how… Continue Reading
The Importance of Patient Initiated Research and Virtual BioTechs
Sharonne N. Hayes, MD, from the Mayo Clinic, recently authored a blog, “The potential of patient initiated research in studying rare… Continue Reading
The RARE Project Announces Big Team Additions, Setting the Stage For Continued Success Thirty (30) million people in the US and 350 million… Continue Reading
Rare Disease Day 2011: Research, Action and Impact
Updates from MarbleRoad for Rare Disease Day 2011, including events, publications, and a quick shout-out for those fighting rare kidney… Continue Reading